234 related articles for article (PubMed ID: 21371244)
21. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
23. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
24. Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH).
Kozminski MA; Wei JT; Nelson J; Kent DM
BJU Int; 2015 Feb; 115(2):308-16. PubMed ID: 24825577
[TBL] [Abstract][Full Text] [Related]
25. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
26. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
27. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
28. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men.
Fowke JH; Signorello LB; Chang SS; Matthews CE; Buchowski MS; Cookson MS; Ukoli FM; Blot WJ
Cancer; 2006 Nov; 107(10):2361-7. PubMed ID: 17031814
[TBL] [Abstract][Full Text] [Related]
29. Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
Arace J; Flores V; Monaghan T; Robins D; Karanikolas N; Winer A; Weiss J
Int J Clin Pract; 2020 Feb; 74(2):e13447. PubMed ID: 31750596
[TBL] [Abstract][Full Text] [Related]
30. Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.
Mandal DM; Sartor O; Halton SL; Mercante DE; Bailey-Wilson JE; Rayford W
Prostate Cancer Prostatic Dis; 2008; 11(3):274-9. PubMed ID: 18268528
[TBL] [Abstract][Full Text] [Related]
31. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
32. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
33. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?
Kaplan SA; Reis RB; Staimen VB; Te AE
Br J Urol; 1998 Dec; 82(6):804-7. PubMed ID: 9883215
[TBL] [Abstract][Full Text] [Related]
34. Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study.
Major JM; Norman Oliver M; Doubeni CA; Hollenbeck AR; Graubard BI; Sinha R
Cancer Causes Control; 2012 Jul; 23(7):1185-91. PubMed ID: 22674292
[TBL] [Abstract][Full Text] [Related]
35. Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study.
Sarma AV; St Sauver JL; Jacobson DJ; McGree ME; Klee GG; Lieber MM; Girman CJ; Hollingsworth JM; Jacobsen SJ;
Urology; 2014 Jan; 83(1):88-93. PubMed ID: 24139354
[TBL] [Abstract][Full Text] [Related]
36. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians.
Sausville J; Naslund M
Int J Clin Pract; 2010 Dec; 64(13):1740-5. PubMed ID: 21070524
[TBL] [Abstract][Full Text] [Related]
37. Differences in lower urinary tract symptoms, treatment and mortality among African-American and white elderly men.
Howard DL; Taylor YJ; Ross LE
J Natl Med Assoc; 2008 Oct; 100(10):1146-52. PubMed ID: 18942275
[TBL] [Abstract][Full Text] [Related]
38. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
39. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
40. African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
Kryvenko ON; Balise R; Soodana Prakash N; Epstein JI
J Urol; 2016 Feb; 195(2):301-6. PubMed ID: 26341575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
